Annotation Detail
Information
- Associated Genes
- FLT3
- Associated Variants
-
FLT3 MUTATION
FLT3 MUTATION - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In a phase 1-2 trial, patients with refractory or relapsed AML with FLT3 mutation received gilteritinib. 40% (100/249) patients achieved a response, with 8% (n=19) achieved complete remission, 4% (n=10) complete remission with imcomplete platelet recovery, 18% (n=48) complete remission with incomplete hematological recovery, and 10% (n=25) partial remission.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7283
- Gene URL
- https://civic.genome.wustl.edu/links/genes/24
- Variant URL
- https://civic.genome.wustl.edu/links/variants/519
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Gilteritinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28645776
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Gilteritinib | Sensitivity | true |